This is a working overview of melanocortin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-22 and is reviewed periodically as new material appears.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Sambhunath De ; (1 February 1915 – 15 April 1985) was an Indian medical scientist and researcher, who discovered the cholera toxin, the animal model of cholera, and successfully demonstrated the method of transmission of cholera pathogen Vibrio cholerae.
Romania is a country in Central and Southeastern Europe. It lies on the lower course of the Danube, north of the Balkan Peninsula, and on the northwestern shore of the Black Sea. It borders Ukraine to the north and east, Hungary to the west, Serbia to the southwest, Bulgaria to the south, Moldova to the east, and the Black Sea to the southeast. It is the twelfth-largest country in Europe by area, covering 238,397 km2 (92,046 mi2), and the sixth-most populous member state of the European Union, with 19 million inhabitants. Administratively, Romania is divided into 41 counties, the largest being Timiș County. The capital, largest city and economic centre is Bucharest. Other major cities and metropolitan areas include Timișoara (TMA), Iași (IMA), Constanța (CMA) and Cluj-Napoca (CMA). Romania was settled during the Lower Paleolithic, later becoming Dacia before Trajan's Dacian Wars and Romanisation. The modern Romanian state was formed in 1859 with the unification of Moldavia and Wallachia under Alexandru Ioan Cuza, becoming the Kingdom of Romania in 1881 under Carol I of Romania. Romania gained independence from the Ottoman Empire in 1877, formalised by the Treaty of Berlin. After World War I, Transylvania, Banat, Bukovina, and Bessarabia joined the Old Kingdom, forming Greater Romania, which reached its largest territorial extent. In 1940, under Axis pressure, Romania lost territories to Hungary, Bulgaria, and the Soviet Union. Following the Act of 23 August, Romania switched sides to join the Allies.
Comecon Frascati Manual German Marshall Fund Good laboratory practice International organisations in Europe International Transport Forum List of country groupings List of multilateral free trade agreements Marshall Plan OECD Anti-Bribery Convention OECD Better Life Index OECD Environmental Performance Reviews OECD Working Party on SMEs and Entrepreneurship Official development assistance Organization for Security and Co-operation in Europe Transfer pricing
Ádám István Mechler is a materials scientist and academic most known for his research on intermolecular interactions in physical chemistry, as well as on molecular machines, hierarchical metamaterials, and self-assembling systems inspired by biology. He is a professor of Chemistry at La Trobe University, Australia, where he leads the Bioinspired self-assembling nanostructures research group. He is also the Academic Program Director of the IIT Kanpur - La Trobe University Research Academy and the BITS Pilani - La Trobe University joint PhD program.
== Civilian airfields == A few civilian airfields, such as Clinton-Sherman Airport, were originally SAC bases. The long-length runways were maintained, as well as the Christmas tree alert structure for possible reuse by SAC forces in the event of nuclear war.
Sources: en.wikipedia.org
=== Picking and ripening === To facilitate transportation and storage, tomatoes are often picked unripe (green) and ripened in storage with the plant hormone ethylene. At industrial scale, such as for canning, tomatoes are picked mechanically. The machine cuts the whole vine and uses sensors to separate ripe tomatoes from the rest of the plant, which is returned to the farm for use either as green manure or to be grazed by livestock.
== See also == Asthenia Debility Exercise intolerance § Low ATP reservoir in muscles (inherited or acquired) Fatigue Central fatigue Malaise Metabolic myopathy Myogenic hyperuricemia (due low ATP reservoir in muscle cell) Muscle weakness Paresis
According to the records compiled by the United States Sentencing Commission, in 2009, the United States Department of Justice typically convicted a little over 81,000 people; of this, approximately 800 were convicted of money laundering as the primary or most serious charge. The Anti-Drug Abuse Act of 1988 expanded the definition of financial institution to include businesses such as car dealers and real estate closing personnel and required them to file reports on large currency transactions. It required verification of identity of those who purchase monetary instruments over $3,000. The Annunzio-Wylie Anti-Money Laundering Act of 1992 strengthened sanctions for BSA violations, required so called "Suspicious Activity Reports" and eliminated previously used "Criminal Referral Forms", required verification and recordkeeping for wire transfers and established the Bank Secrecy Act Advisory Group (BSAAG). The Money Laundering Suppression Act from 1994 required banking agencies to review and enhance training, develop anti–money laundering examination procedures, review and enhance procedures for referring cases to law enforcement agencies, streamline the currency transaction report exemption process, required each money services business (MSB) to be registered by an owner or controlling person, required every MSB to maintain a list of businesses authorized to act as agents in connection with the financial services offered by the MSB, made operating an unregistered MSB a federal crime, and recommended that states adopt uniform laws applicable to MSBs.
== External links == United States FDA links to actions United States NIH Factsheet regarding weight loss and athletic performance Dietary Supplements: Balancing Consumer Choice and Safety. A report of the New York State Task Force on Life & the Law. The history of Ephedra (ma-huang).
Sources: en.wikipedia.org
1993/974) Road Traffic Act 1991 (Commencement No. 6) Order 1993 (S.I. 1993/975) Protection of Wrecks (Designation No. 1) Order 1993 (S.I. 1993/976) Banking Appeal Tribunal (Amendment) Regulations 1993 (S.I. 1993/982) Building Societies Appeal Tribunal (Amendment) Regulations 1993 (S.I. 1993/983) Building Societies (Prescribed Contracts) Order 1993 (S.I. 1993/984) Building Societies (Designation of Qualifying Bodies) Order 1993 (S.I. 1993/985) Sale of Registration Marks (Amendment) Regulations 1993 (S.I. 1993/986) Retention of Registration Marks Regulations 1993 (S.I. 1993/987) Retention of Registration Marks Regulations 1992 (Amendment) Regulations 1993 (S.I. 1993/988) Building Societies (Designation of Qualifying Bodies) (No. 2) Order 1993 (S.I. 1993/989) Animals, Meat and Meat Products (Examination for Residues and Maximum Residue Limits) (Amendment) Regulations 1993 (S.I. 1993/990) Tayside Region (Electoral Arrangements) Order 1993 (S.I. 1993/991) Dumfries and Galloway Region (Electoral Arrangements) Order 1993 (S.I. 1993/992) National Health Service (Appointment of Consultants) (Scotland) Regulations 1993 (S.I. 1993/994) Assured Tenancies (Exceptions) (Scotland) Amendment Regulations 1993 (S.I. 1993/995) Environmentally Sensitive Areas (Central Southern Uplands) Designation Order 1993 (S.I. 1993/996) Environmentally Sensitive Areas (Western Southern Uplands) Designation Order 1993 (S.I. 1993/997) Education (School Curriculum and Related Information) (Amendment) (Wales) Regulations 1993 (S.I. 1993/998)
Hydrothermal plumes are fluid entities that manifest where hydrothermal fluids are expelled into the overlying water column at active hydrothermal vent sites. As hydrothermal fluids typically harbor physical (e.g., temperature, density) and chemical (e.g., pH, Eh, major ions) properties distinct from seawater, hydrothermal plumes embody physical and chemical gradients that promote several types of chemical reactions, including oxidation-reduction reactions and precipitation reactions. Hydrothermal vent fluids harbor temperatures (~40 to >400 °C) well above that of ocean floor seawater (~4 °C), meaning that hydrothermal fluid is less dense than the surrounding seawater and will rise through the water column due to buoyancy, forming a hydrothermal plume; therefore, the phase during which hydrothermal plumes rise through the water column is known as the "buoyant plume" phase. During this phase, shear forces between the hydrothermal plume and surrounding seawater generate turbulent flow that facilitates mixing between the two types of fluids, which progressively dilutes the hydrothermal plume with seawater. Eventually, the coupled effects of dilution and rising into progressively warmer (less dense) overlying seawater will cause the hydrothermal plume to become neutrally buoyant at some height above the seafloor; therefore, this stage of hydrothermal plume evolution is known as the "nonbuoyant plume" phase.
==== Commercial ==== WNCB-FM (93.9 B939 FM, Country) WQDR-FM (94.7QDR, Country) WDCG-HD2 (ALT 95.3, Throwback Hits, analog broadcast on 95.3 FM W237BZ) WBBB-FM 96.1 (Radio 96.1, Adult hits) WPLW-FM (96.9 Pulse FM, Contemporary hits) WQOK-FM (K97.5, Hip hop) WRDU-FM (100.7, Classic rock) WRAL-FM (Mix 101.5, Adult contemporary) WKIX-FM (KIX 102.9, Classic hits) WNNL-FM (103.9 The Light, Urban contemporary gospel) WDCG-FM (G105, Contemporary hit radio) WTKK-FM (106.1 FM, News/Talk) WFXC-FM/WFXK-FM (Foxy 107/104, Urban adult contemporary) WQDR-AM (570, classic rock) WPTF-AM (NewsRadio 680, News/Talk) 750 WAUG (Hot 97.9, Mainstream urban WKIX (Just Right Radio 850 and 93.5 FM, Popular standards)
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.